The effect of insulin aspart on postprandial glucose and the excursion of serum glucose level in type 2 diabetic patients managed with delivered in insulin pump therapy
10.3760/cma.j.issn.1673-4904.2009.31.003
- VernacularTitle:门冬胰岛素应用于胰岛素泵对餐后血糖和血糖波动的影响
- Author:
Jindan WU
;
Xiaohua XU
;
Gu GAO
;
Yunli REN
;
Lanlan JIANG
;
Ying ZHANG
;
Xiaojun TAO
;
Jianhua MA
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Insulin infusion system;
Drug therapy;
Insulin aspart
- From:
Chinese Journal of Postgraduates of Medicine
2009;32(31):6-8
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy of insulin aspart and human soluble insulin on postprandial glucose control and blood glucose excursion in type 2 diabetic patients managed with insulin pump therapy. Methods All of 345 hospitalized type 2 diabetic patients were randomized divided into two groups. One group underwent insulin pump therapy with insulin aspart (aspart group, 173 cases),another group with human soluble insulin (humulin R group, 172 cases). Capillary glucose concentrations were measured at 9 time points,including preprandial,2 hours postprandial,bedtime (22:00),midnight(0:00) and 3:00 every day during the treatment. The change of blood glucose at each time point and the variation of postprandial blood glucose excursion was compared between the two groups. The frequency of hypoglycemia was also evaluated. Results After treatment, fasting blood glucose and post breakfast and post dinner blood glucose levels were decreased more significantly in the aspart group than those in the humulin R group. And a significantly smaller postprandial blood glucose excursion was shown in the aspart group compared with that in the humulin R group (P< 0.05). The time to achieve good glycemic control in the aspart group was (4.40 ± 2.16) d, significantly shorter than that in the humulin R group[(5.68 ± 2.29) d](P< 0.05). The incidence of hypoglycemia was significantly lower in the aspart group (P <0.05). Conclusion Insulin aspart results in better control of blood glucose and less glycemic variability compare with human soluble insulin in type 2 diabetic patients during delivery by continuous subcutaneous insulin infusion.
